OrbiMed Genesis GP LLC
CIK 1808744
Transactions on file
64
Open-market buys
18
Win rate (buys)
89%
18 scored
Avg % since filing (buys)
+315.1%
Tickers traded
Recent activity
| Filed | Txn date | Issuer | Roles | Code | Shares | Value | % since Filing | Filing |
|---|---|---|---|---|---|---|---|---|
| 2026-09-23 | 2026-09-21 | ETRA Electra Therapeutics, Inc. | Director10% | Buy | 1,000,000 | $15.00M | -24.5% | open → |
| 2026-09-23 | 2026-09-21 | ETRA Electra Therapeutics, Inc. | Director10% | C | 758,279 | $0.00 | — | open → |
| 2026-09-23 | 2026-09-21 | ETRA Electra Therapeutics, Inc. | Director10% | Buy | 333,333 | $5.00M | -24.5% | open → |
| 2026-09-23 | 2026-09-21 | ETRA Electra Therapeutics, Inc. | Director10% | C | 1,703,314 | $0.00 | — | open → |
| 2026-09-23 | 2026-09-21 | ETRA Electra Therapeutics, Inc. | Director10% | C | 1,087,934 | $0.00 | — | open → |
| 2026-09-23 | 2026-09-21 | ETRA Electra Therapeutics, Inc. | Director10% | C | 2,002,310 | $0.00 | — | open → |
| 2026-08-11 | 2026-08-07 | BRVE Braveheart Bio, Inc. | Director10% | Buy | 273,333 | $4.92M | +60.6% | open → |
| 2026-08-11 | 2026-08-07 | BRVE Braveheart Bio, Inc. | Director10% | Buy | 1,666,667 | $30.00M | +60.6% | open → |
| 2026-08-11 | 2026-08-07 | BRVE Braveheart Bio, Inc. | Director10% | C | 9,132,420 | $0.00 | — | open → |
| 2026-06-24 | 2026-06-22 | ELVN Enliven Therapeutics, Inc. | 10% | Sale | 46,776 | $2.10M | +2.2% | open → |
| 2026-06-24 | 2026-06-22 | ELVN Enliven Therapeutics, Inc. | 10% | Sale | 787,024 | $35.72M | +1.4% | open → |
| 2026-06-24 | 2026-06-22 | ELVN Enliven Therapeutics, Inc. | 10% | Sale | 1,477 | $66.5K | +2.2% | open → |
| 2026-06-24 | 2026-06-22 | ELVN Enliven Therapeutics, Inc. | 10% | Sale | 24,846 | $1.13M | +1.4% | open → |
| 2026-06-17 | 2026-06-15 | ELVN Enliven Therapeutics, Inc. | 10% | Sale | 272,322 | $12.26M | +2.2% | open → |
| 2026-06-17 | 2026-06-15 | ELVN Enliven Therapeutics, Inc. | 10% | Sale | 9,086 | $409.1K | +2.2% | open → |
| 2026-06-02 | 2026-05-28 | QTTB Q32 Bio Inc. | Director10% | Buy | 625,000 | $5.00M | +9.6% | open → |
| 2026-06-02 | 2026-05-28 | QTTB Q32 Bio Inc. | Director10% | Buy | 1,250,000 | $10.00M | +9.6% | open → |
| 2026-04-23 | 2026-04-21 | PRLD Prelude Therapeutics Inc | Director10% | Buy | 1,126,126 | $5.00M | +10.6% | open → |
| 2026-04-23 | 2026-04-21 | PRLD Prelude Therapeutics Inc | Director10% | Buy | 1,689,189 | $7.50M | +10.6% | open → |
| 2026-04-09 | 2026-04-08 | ACET Adicet Bio, Inc. | 10% | Sale | 40,416 | $263.5K | +47.1% | open → |
| 2026-04-09 | 2026-04-08 | ACET Adicet Bio, Inc. | 10% | Sale | 32,523 | $204.6K | +52.5% | open → |
| 2026-04-09 | 2026-04-07 | ACET Adicet Bio, Inc. | 10% | Sale | 2,400 | $15.3K | +50.3% | open → |
| 2026-04-09 | 2026-04-07 | ACET Adicet Bio, Inc. | 10% | Sale | 29,319 | $191.5K | +46.9% | open → |
| 2025-02-19 | 2025-02-14 | MBX MBX Biosciences, Inc. | Director10% | Buy | 29,540 | $291.0K | +523.6% | open → |
| 2025-02-19 | 2025-02-18 | MBX MBX Biosciences, Inc. | Director10% | Buy | 49,070 | $531.9K | +466.6% | open → |
| 2025-02-19 | 2025-02-14 | MBX MBX Biosciences, Inc. | Director10% | Buy | 17,962 | $177.8K | +520.4% | open → |
| 2025-02-19 | 2025-02-18 | MBX MBX Biosciences, Inc. | Director10% | Buy | 94,100 | $1.02M | +466.6% | open → |
| 2025-03-12 | 2025-03-10 | IRON Disc Medicine, Inc. | Director | Sale | 68,766 | $3.73M | +19.6% | open → |
| 2025-03-12 | 2025-03-12 | IRON Disc Medicine, Inc. | Director | Sale | 10,733 | $584.3K | +19.3% | open → |
| 2025-03-12 | 2025-03-10 | IRON Disc Medicine, Inc. | Director | Sale | 106,384 | $5.78M | +19.6% | open → |
| 2025-03-12 | 2025-03-10 | IRON Disc Medicine, Inc. | Director | Sale | 26,596 | $1.44M | +19.6% | open → |
| 2025-03-12 | 2025-03-10 | IRON Disc Medicine, Inc. | Director | Sale | 136 | $7.5K | +18.0% | open → |
| 2025-03-12 | 2025-03-10 | IRON Disc Medicine, Inc. | Director | Sale | 211 | $11.6K | +18.0% | open → |
| 2025-03-12 | 2025-03-10 | IRON Disc Medicine, Inc. | Director | Sale | 53 | $2.9K | +18.0% | open → |
| 2025-03-12 | 2025-03-11 | IRON Disc Medicine, Inc. | Director | Sale | 9,222 | $498.1K | +20.2% | open → |
| 2025-03-12 | 2025-03-11 | IRON Disc Medicine, Inc. | Director | Sale | 14,267 | $770.6K | +20.2% | open → |
| 2025-03-12 | 2025-03-11 | IRON Disc Medicine, Inc. | Director | Sale | 3,567 | $192.7K | +20.2% | open → |
| 2025-03-12 | 2025-03-12 | IRON Disc Medicine, Inc. | Director | Sale | 603 | $33.2K | +17.9% | open → |
| 2025-03-12 | 2025-03-12 | IRON Disc Medicine, Inc. | Director | Sale | 933 | $51.4K | +17.9% | open → |
| 2025-03-12 | 2025-03-12 | IRON Disc Medicine, Inc. | Director | Sale | 233 | $12.8K | +17.9% | open → |
| 2025-03-12 | 2025-03-12 | IRON Disc Medicine, Inc. | Director | Sale | 42,930 | $2.34M | +19.3% | open → |
| 2025-03-12 | 2025-03-12 | IRON Disc Medicine, Inc. | Director | Sale | 27,750 | $1.51M | +19.3% | open → |
| 2025-03-21 | 2025-03-20 | IRON Disc Medicine, Inc. | Director | Sale | 364 | $19.7K | +20.2% | open → |
| 2025-03-21 | 2025-03-20 | IRON Disc Medicine, Inc. | Director | Sale | 1,457 | $78.7K | +20.2% | open → |
| 2025-03-21 | 2025-03-20 | IRON Disc Medicine, Inc. | Director | Sale | 941 | $50.8K | +20.2% | open → |
| 2025-03-21 | 2025-03-19 | IRON Disc Medicine, Inc. | Director | Sale | 5,228 | $282.4K | +20.2% | open → |
| 2025-03-21 | 2025-03-19 | IRON Disc Medicine, Inc. | Director | Sale | 20,911 | $1.13M | +20.2% | open → |
| 2025-03-21 | 2025-03-19 | IRON Disc Medicine, Inc. | Director | Sale | 13,517 | $730.2K | +20.2% | open → |
| 2025-03-21 | 2025-03-21 | IRON Disc Medicine, Inc. | Director | Sale | 1,320 | $71.3K | +20.2% | open → |
| 2025-03-21 | 2025-03-21 | IRON Disc Medicine, Inc. | Director | Sale | 5,279 | $285.1K | +20.2% | open → |
| 2025-03-21 | 2025-03-21 | IRON Disc Medicine, Inc. | Director | Sale | 3,412 | $184.2K | +20.2% | open → |
| 2025-03-26 | 2025-03-24 | IRON Disc Medicine, Inc. | Director | Sale | 1,956 | $105.8K | +20.0% | open → |
| 2025-03-26 | 2025-03-24 | IRON Disc Medicine, Inc. | Director | Sale | 3,026 | $163.7K | +20.0% | open → |
| 2025-03-26 | 2025-03-24 | IRON Disc Medicine, Inc. | Director | Sale | 756 | $40.9K | +20.0% | open → |
| 2025-04-04 | 2025-04-03 | EWTX Edgewise Therapeutics, Inc. | Director10% | Buy | 372,578 | $7.50M | +121.7% | open → |
| 2025-04-04 | 2025-04-03 | EWTX Edgewise Therapeutics, Inc. | Director10% | Buy | 124,193 | $2.50M | +121.7% | open → |
| 2025-04-11 | 2025-04-09 | CMPX Compass Therapeutics, Inc. | Director10% | Sale | 3,571,428 | $5.68M | -30.2% | open → |
| 2025-12-18 | 2025-11-21 | KROS Keros Therapeutics, Inc. | Director | Disp. | 74,465 | $1.32M | -37.0% | open → |
| 2025-12-18 | 2025-11-21 | KROS Keros Therapeutics, Inc. | Director | Disp. | 140,057 | $2.49M | -37.0% | open → |
| 2025-10-10 | 2025-10-08 | ACET Adicet Bio, Inc. | 10% | Buy | 3,500,000 | $3.50M | +859.0% | open → |
| 2025-10-10 | 2025-10-08 | ACET Adicet Bio, Inc. | 10% | Buy | 1,500,000 | $1.50M | +859.0% | open → |
| 2025-07-30 | 2025-07-25 | IKNA ImageneBio, Inc. | Director | Grant | 83,611 | $208.2K | — | open → |
| 2025-09-02 | 2025-08-25 | STTK Shattuck Labs, Inc. | Director | Buy | 1,051,021 | $914.4K | +810.3% | open → |
| 2025-09-02 | 2025-08-25 | STTK Shattuck Labs, Inc. | Director | Buy | 5,255,106 | $4.57M | +810.3% | open → |
